“In five years, we have built a world-leading group that offers something unique – namely a bio convergence revolution. This concept is so strong and guiding for us that we decided to name the company after it. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D printing with biology, we contribute to our customers being able to improve people's lives for the better. We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future”, says Erik Gatenholm, President and CEO of BICO.
Change of ticker from CLNK to BICO
The shares’ short name (ticker) will change from CLNK to BICO. The company’s ISIN code and order book ID will be unchanged. The last day for trading in the share's current ticker will be Friday August 13, 2021. The first day for trading in the share's new ticker will be on Monday August 16, 2021. This is an administrative matter and shareholders do not need to take any action.
Launch of BICO
Launch of the new company name with logo and visual identity in connection with the publication of the interim report for January-June 2021 on August 18, 2021.
Publication of the first interim report as BICO Group AB (publ)
The interim report January-June 2021 will be the first BICO Group AB (publ) report. The report will be published on August 18 at 08.00 (CEST) and will be available at www.bico.com and www.bico.com/investors. BICO arranges an earnings call at 14.00 (CEST) the same day. For more information about the earnings call, click here.
Press releases and news from BICO
Press releases and news from will onwards be sent with BICO Group AB (publ) as sender. All history and data from when the company was called CELLINK AB (publ) is archived in the press release section. Until August 18, www.cellink.com/investors is being used and from August 18, visit www.bico.com/investors.
BICO is the parent company of the Group and the subsidiaries to keep their names
The Group consists of 11 subsidiaries divided into three business areas: Bioprinting (CELLINK, MatTek, Visikol and Nanoscribe), Biosciences (CYTENA, CYTENA Bioprocess Solutions, Dispendix and Discover Echo) and Bioautomation (SCIENION, CELLENION and Ginolis).
The name change only applies to the parent company for the Group and not the subsidiaries. They will keep their names. CELLINK is and remains a world-leading brand in 3D bioprinting. CELLINK is a wholly owned subsidiary of BICO and will continue its goal-oriented work with a focus on bioprinting of human organs and tissues. For more information about CELLINK’s innovative product portfolio and offering within 3D bioprinting, please visit www.cellink.com.
For more information, please contact:
|Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
|Isabelle Ljunggren, Head of Communications
Phone: +46 708 30 08 90
The information was submitted for publication, through the agency of the contact persons set out above on August 12, 2021 at 3.10pm (CEST).